53results about How to "Increase fluorescence signal intensity" patented technology

The invention relates to a nicking endonuclease-based netted rolling cycle amplification system and a use thereof. Based on the existing second-generation hyperbranched rolling cycle amplification technology, the amplification system utilizes a special endonuclease which is nicking endonuclease Nb.BsrDI so that a third-generation rolling cycle amplification technology which is a netted rolling cycle amplification (NGCA) technology is produced. Intensity of fluorescence signals produced by the netted rolling cycle amplification is increased with increasing of a target DNA concentration, is obviously stronger than that of fluorescence signals produced by linear rolling cycle amplification and hyperbranched rolling cycle amplification and has a detection limit of 0.1fM. Compared with the first-generation linear rolling cycle amplification and the second-generation hyperbranched rolling cycle amplification, the nicking endonuclease-based netted rolling cycle amplification system retains the prior art advantages in operationality, use cost and amplification time, further realizes signal amplification based on the prior art thereby providing good technical conditions for ultralow-abundance nucleic acid sample analysis and detection, and has a wide application prospect.

The invention discloses a fluorescent probe, a method for detecting tetracycline and an application of the fluorescent probe. The probe comprises a tetracycline monoclonal antibody and a signal carrier, wherein the signal carrier is an amino-functionalized aluminum nanosheet, and the particle size of the amino-functionalized aluminum nanosheet is 520-570nm. According to the invention, the probe isconstructed by a fluorescent metal organic framework material in immunochromatographic test strip detection for the first time, and a simple, novel, sensitive and rapid analysis system is developed for tetracycline detection of meat, milk, honey and other actual samples. The lowest detection limit of the provided test strip on tetracycline is 0.0516 ng / mL, and the value of the lowest detection limit is less than that reported by many other literatures.

The invention discloses an osteosarcoma circulating tumor cell identification kit. The kit comprises capture probes for marker gene mRNAs and a signal amplification system. The marker genes comprise at least two epithelial cell marker genes selected from EpCAM, CDH1, KRT8, KRT16, KRT17, KRT18, KRT19 and KRT20 and at least two osteosarcoma metastasis-related interstitial cell marker genes selected from MMP2, MMP9, VIM, CDH2, FN1, HIF-1a, SERPINE1, SURVIVIN, TWIST1, AKT2 and SNAIL. The kit can completely detect osteosarcoma circulating tumor cells, evaluate their metastatic ability to avoid the possibility of the false negative result caused by different expression levels of CTCs in different types of cancers and further improve the accuracy of detection.

The invention relates to an ovarian cancer-related microRNA detection kit. In accordance with each to-be-detected ovarian cancer-related microRNA, the detection kit comprises at least one first-grade signal amplification probe, at least one second-grade signal amplification probe and at least one third-grade signal amplification probe, as well as a capture probe, wherein a P1 sequence of the capture probe of the ovarian cancer-related microRNA is selected from SEQ ID NO.1-SEQ ID NO.8. According to the detection kit provided by the invention, the selected capture probe and signal amplification probes, a hybridization reaction can be conducted under a uniform reaction condition, and non-specific binding can be avoided between the various probes; and the designed probes are good in specificity and high in signal-to-noise ratio in detection. Meanwhile, by combining the various probes, a system, which is complete in detection effect, is formed by the identifying kit and a detection method.

The invention relates to a breast cancer related microRNA (Ribonucleic Acid) detection kit. The breast cancer related microRNA detection kit comprises at least one first-stage signal amplification probe, at least one second-stage signal amplification probe, at least one third-stage signal amplification probe and a capture probe which are provided for each kind of to-be-detected breast cancer related microRNA, wherein the P1 sequence of the capture probe of the breast cancer related microRNA is selected from SEQ ID NO. 1 to SEQ ID NO. 8. According to the breast cancer related microRNA detection kit disclosed by the invention, hybridization reaction can be carried out by the capture probe and the signal amplification probes which are selected by the breast cancer related microRNA detection kit under a uniform reaction condition, and all probes are not in nonspecific binding; the designed probes have good specificity and high signal-to-noise ratio during detection; meanwhile, a system with a good detection effect is formed by an identification kit and a detection method through combined use of multiple probes.

The invention relates to a circulating gastric tumor cell identifying kit. The identifying kit, in accordance with each marker gene mRNA, comprises a capture probe, an amplification probe and a marking probe, wherein the marker gene mRNAs include three varieties: gastric tumor cell marker gene mRNA selected from at least one of CEA and HER2, epithelial cell marker gene selected from at least one of KRT7, KRT8, KRT17, KRT18, KRT19 and KRT20, and mesenchymal cell marker gene selected from at least one of AKT2, HIF-1A, TWIST1 and VIMENTIN. The identifying kit provided by the invention, which adds detection on gastric tumor cell marker gene on the basis of CTCs epithelial cell marker genes and mesenchymal cell marker genes which are common in various tumors, can avoid a false positive result caused by such factors as non-tumor epithelial cells in blood, the introduction of normal epithelial cells to a sampling process and the like, so that the detected epithelial cell marker gene and / or mesenchymal cell marker gene cells are circulating gastric tumor cells; and the accuracy and reliability of a detection result can be further enhanced.

The invention discloses a method for improving the sensitivity of an immunochromatographic marker, which comprises the following steps of coupling an antibody with fluorescent microspheres to obtain an antibody-fluorescent microsphere conjugate, and coupling the antibody-fluorescent microsphere conjugate with the fluorescent microspheres again to obtain an enhanced antibody-fluorescent microsphereconjugate as the immunochromatographic marker. According to the method, the labeled antibody-fluorescent microsphere conjugate is coupled again, so that the same antibody can carry more fluorescent microspheres, the strength of fluorescent substances on a detection line is greatly improved, and the sensitivity of a reagent is improved. The invention also discloses an application of the method ininterleukin 6 detection.

The invention relates to a composite micro-nano structure array on a high light-transmission substrate and a method and application of the same. The invention is characterized in that micro-nano structure arrays of light guide materials on the high light-transmission substrate are taken as supporting structures of fluorescent conjugated polymers for detection. The method comprises: firstly, preparing the micro-nano structure arrays and secondary structure arrays of the light guide materials on the high light-transmission material substrate such as quartz and the like; and secondly, coating the fluorescent conjugated polymers which are sensitive to specified analyte on the surface of the nano structure substrate to form the composite micro-nano structure array which is used for detecting an object. The invention takes the micro-nano structure arrays of different light guide materials as adhesive substrates of the fluorescent conjugated polymers and utilizes the advantages of micro-nanostructures such as large specific surface area, evanescent wave effect, micro resonant cavity action and the like to improve the sensitivity of detection and the signal intensity, prolong the servicelife and improve the reutilization property. The composite micro-nano structure array on the high light-transmission substrate can be applied to the detection of the specificity and high sensitivity of solid, liquid and gas molecules.

The invention relates to a lung cancer early screening kit. The kit comprises capture probes, amplification probes and labeled probes for detection of target gene mRNAs. The target genes comprise lung cancer screening genes and non-blood cell related genes. The lung cancer screening genes comprise at least two of TTF-1, LUNX, NSE, EGFR, P63 and CEA. The non-blood cell related genes comprise at least two of CK7, CK19, hTERT, VIM, PIM-1 and Survivin. Through screening of target genes, detection of a single target gene is realized and simultaneous detection of multiple target genes is realized so that lung cancer early screening cells can be completely detected, leukocytes, hematopoietic stem cells and endothelial cells in blood are distinguished from the screening cells, false negative and false positive results are avoided and the accuracy of detection is further improved.

The invention discloses a novel parathyroid gland detection device which is composed of a probe, a handle, an external optical fiber cable and a host, a probe lens is arranged at the top end of the probe, the host comprises a cassette, an internal optical fiber cable, a laser emission unit, a fluorescence detection unit and a controller, and the external optical fiber cable and the internal optical fiber cable both adopt a single optical fiber design. The cassette comprises a laser light source, a photoelectric sensor, a first lens and a second lens, the laser light source is provided with a laser filtering cover, the surface of the photoelectric sensor is covered with a fluorescent filtering film, and the laser light source is placed on the photoelectric sensor. The parathyroid gland detection device is simple in structure, laser density can be improved, fluorescence signal intensity is enhanced, and accordingly parathyroid gland detection and recognition rate is improved.

The invention discloses a circulating tumor cell identification kit and a circulating tumor cell identification method. The circulating tumor cell identification kit comprises a detection probe for detecting mRNA of an epithelial cell marking gene and / or mRNA of a mesenchymal cell marking gene, wherein the epithelial cell marking gene is selected from one or more of CDH2, VIMENTIN, FN1 and AKT2. Multiple RNA probes are adopted in the identification method, specific genes of a plurality of circulating tumor cells (CTCs) can be marked at the same time and are divided into genes I (epithelial genes), genes II (epithelial-mesenchymal genes) and genes III (mesenchymal genes), and false positive results caused by lack of part of the specific genes of the CTCs in a process that the CTCs enter peripheral blood for circulation are reduced; the method can be finished within eight hours, and a single copied mRNA hybridization probe is combined with a corresponding fluorescent probe by virtue of a signal amplification system, so that the detection sensitivity of in-situ RNA (Ribonucleic Acid) hybridization is remarkably improved.

The invention provides an InDel site genotyping method. The InDel site genotyping method comprises the following steps: (1) carrying out T vector clone sequencing on a DNA sequence of a targeted gene to obtain a targeted gene cloning product sequence, and carrying out multi-comparison on the targeted gene cloning product sequence to obtain an InDel site; and (2) designing a PCR amplification primer according to the InDel site, wherein the PCR amplification primer comprises a forward primer and a reverse primer, and a 5' tail end of the forward primer is modified by a fluorophore; and (3) carrying out PCR amplification on DNA of a sample to be detected by the PCR amplification primer to obtain an amplification product, and detecting the amplification product by fluorescent capillary gel electrophoresis to determine the genotype of the InDel site in the sample to be detected. The provided genotyping method is low in cost, simple and flexible to operate and accurate in result.

The invention relates to a lung cancer related mciroRNA detection kit. The lung cancer related mciroRNA detection kit comprises: at least one first-grade signal amplification probe aiming at each type of lung cancer related mciroRNA to be detected, at least one second-grade signal amplification probe, at least one third-grade signal amplification probe and a capturing probe; and a P1 sequence of the capturing probe of the lung cancer related mciroRNA is selected from SEQ ID NO.1 to SEQ ID NO.21. The capturing probe and the signal amplification probes, selected by the invention, can be subjected to hybridization reaction under uniform reaction conditions, and all the probes are not in non-specifical combination; and the designed probes have good specificity and high signal-to-noise ratio. Meanwhile, a plurality of types of probes are combined so that a system with a complete detection effect is formed by utilizing an identification kit and a detection method.

The invention relates to a protein typing kit of circulating tumor cells. The kit comprises capture antibodies against different CTCs marker proteins and labeled antibodies against different CTCs marker proteins. The CTCs marker proteins comprise epithelial cell marker proteins and interstitial cell marker proteins. The epithelial cell marker proteins are selected from EPCAM, E-cadherin, KRT5, KRT7, KRT-8, KRT-16, KRT-17, KRT-18, KRT-19, KRT-20. The interstitial cell marker proteins are selected from N-cadherin, vimentin, fibronectin, MMP2, MMP3, MMP9, AKT2, ZEB1, FOXC1, FOXC2, SNAI1, SNAI2, SERPINE1. The marker proteins selected in the invention can realize detection of single marker protein, and a single marker protein can be used with other marker proteins for the detection. Therefore, circulating tumor cells can be fully detected, and the cell type can be distinguished. And then, false negative results caused by difference of expression levels of some marker proteins among individual circulating tumor cells are avoided.